Point72 Hong Kong Ltd grew its stake in Qiagen (NYSE:QGEN – Free Report) by 26.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 23,572 shares of the company’s stock after acquiring an additional 4,893 shares during the period. Point72 Hong Kong Ltd’s holdings in Qiagen were worth $969,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently modified their holdings of the company. Riverview Trust Co bought a new position in shares of Qiagen in the first quarter valued at about $28,000. Toronto Dominion Bank acquired a new stake in Qiagen during the second quarter worth about $27,000. Park Place Capital Corp acquired a new stake in Qiagen during the first quarter worth about $36,000. Quarry LP acquired a new stake in Qiagen during the fourth quarter worth about $38,000. Finally, CWM LLC grew its stake in Qiagen by 19.1% during the first quarter. CWM LLC now owns 2,236 shares of the company’s stock worth $96,000 after buying an additional 358 shares in the last quarter. 70.00% of the stock is owned by institutional investors.
Qiagen Stock Down 1.7 %
Shares of NYSE QGEN opened at $44.11 on Thursday. The company has a 50 day simple moving average of $45.06 and a 200 day simple moving average of $43.48. The firm has a market cap of $10.07 billion, a PE ratio of 29.58, a price-to-earnings-growth ratio of 3.17 and a beta of 0.39. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46.
Analysts Set New Price Targets
QGEN has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 18th. Robert W. Baird raised their price target on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research note on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Qiagen presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.10.
Get Our Latest Analysis on Qiagen
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Read More
- Five stocks we like better than Qiagen
- How to Invest in Blue Chip Stocks
- Should You Invest in Treasury Bills?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGEN – Free Report).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.